Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 3, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

April 1, 2025

Conditions

Recurrent Liver Cancer After Liver Transplantation

Interventions

DRUG

Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab

Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC

Trial Locations (1)

RECRUITING

Department of Liver Transplantation, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Shuhong Yi

OTHER